aTyr Pharma completes Phase 3 enrollment in pulmonary sarcoidosis; topline data Q3 2025

aTYR PHARMA INC

2024-Q3 EPS reported -$0.69 revenue$235,000

Phase 3 EFZO-FIT enrolled 268 patients (target exceeded) at 85 centers in 9 countries; topline data expected Q3 2025.
Cash, equivalents, and investments $68.9M at Sep 30, 2024; raised ~$19.4M in ATM offering post-quarter.
R&D expenses $14.8M and G&A $3.3M in Q3 2024; cash runway projected through BLA filing for efzofitimod.
Publication in European Respiratory Journal showed significant reduction in corticosteroid relapse with efzofitimod.
Phase 2 EFZO-CONNECT in SSc-ILD enrolling; interim data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.